rabbit anti glut1 antibody  (Bioss)

Journal: Redox Biology

Article Title: Porcine epidemic diarrhea virus promotes viral replication via ROS/HIF-1α-mediated glycolysis

doi: 10.1016/j.redox.2026.104008

Figure Lengend Snippet: PEDV infection reprograms host metabolism toward aerobic glycolysis. ST cells were infected with PEDV at an MOI of 1 for 24 h. (A) Metabolic heatmap showing relative abundance of glycolytic and TCA cycle metabolites in mock- and PEDV-infected cells. Metabolomic data were obtained from four biological replicates per group. Metabolite levels were normalized to mock controls. (B–C) Protein expression of key glycolytic regulators (GLUT1, HK2, PFKM, PFKFB3, and LDHA) and PEDV N protein was analyzed by western blots. β-Tubulin was used as a control. (D–E) Glucose uptake was measured by flow cytometry and quantified as mean fluorescence intensity (MFI). (F) Lactate production was quantified using a lactate assay kit at 24 hpi. (G) Schematic illustration of glucose metabolic reprogramming during PEDV infection, with upregulated metabolites indicated in red and downregulated metabolites in green. Data were presented as mean ± SEM from three independent experiments. ∗ P < 0.05, ∗∗ P < 0.01.

Article Snippet: Glucose Transporter 1 (GLUT1) polyclonal antibody (GLUT1; 21829-1-AP), Hexokinase 2 polyclonal antibody (HK2; 22029-1-AP), phosphofructokinase (PFKM) polyclonal antibody (PFKM; 55028-1-AP), 6-phosphofructo-2-kinase (PFKFB3) polyclonal antibody (PFKFB3; 13763-1-AP), and lactate dehydrogenase A (LDHA)-specific polyclonal antibody (LDHA; 19987-1-AP) were purchased from Proteintech (China).

Techniques: Infection, Metabolomic, Expressing, Western Blot, Control, Flow Cytometry, Fluorescence, Lactate Assay

Journal: BMC Cancer

Article Title: Glucose-transporter 1 (GLUT1) as a prognostic biomarker: evidence from 14,966 human tumors across 134 cancer types

doi: 10.1186/s12885-025-15527-5

Figure Lengend Snippet: Comparison of GLUT1 immunostaining results with previous GLUT1 studies. An „X“ indicates the fraction of GLUT1 positive cancer cells in the present study, dots indicate the reported frequencies from the literature for comparison: red dots mark studies with ≤10 analyzed tumors, yellow dots mark studies with ≥11 ≤ 25 analyzed tumors and green dots mark studies with > 25 analyzed tumors. All studies are listed in supplementary table 1. Locations of specific tumors types include seminoma of the testis, soft tissue rhabdoid tu-mors, teratomas of the testis, and typical as well as typical and atypical neuroendocrine of the lungs

Article Snippet: For the purpose of antibody validation, the normal tissue TMA was also analyzed by the rabbit polyclonal GLUT1 antibody 355 A-15 (Cell Marque, Rocklin, CA, pH 6.0, 1:200) on a DAKO autostainer Link48 according to a protocol suggested by Agilent DAKO.

Techniques: Comparison, Immunostaining

Journal: BMC Cancer

Article Title: Glucose-transporter 1 (GLUT1) as a prognostic biomarker: evidence from 14,966 human tumors across 134 cancer types

doi: 10.1186/s12885-025-15527-5

Figure Lengend Snippet: GLUT1 immunostaining in normal tissue. GLUT1 staining was typically membranous but also cytoplasmic. The panels show strong GLUT1 staining in amnion and chorion cells of the placenta ( A ), predominantly membranous staining in cyto- and syncytiotrophoblasts of a mature placenta ( B ), lack of GLUT1 staining of cerebral cells with a strong staining of small vessel cells in the grey cerebrum ( C ), moderate GLUT1 staining of suprabasal cell layers of the anal skin ( D ), focal weak GLUT1 staining in the surface epithelium of the gallbladder ( E ), weak to moderate GLUT1 staining of few collecting ducts in the renal cortex ( F ), weak GLUT1 staining in basal cells of the prostate ( G ), and lack of GLUT1 staining in sinusoidal cells with strong staining of erythrocytes in the liver ( H )

Article Snippet: For the purpose of antibody validation, the normal tissue TMA was also analyzed by the rabbit polyclonal GLUT1 antibody 355 A-15 (Cell Marque, Rocklin, CA, pH 6.0, 1:200) on a DAKO autostainer Link48 according to a protocol suggested by Agilent DAKO.

Techniques: Immunostaining, Staining

Journal: BMC Cancer

Article Title: Glucose-transporter 1 (GLUT1) as a prognostic biomarker: evidence from 14,966 human tumors across 134 cancer types

doi: 10.1186/s12885-025-15527-5

Figure Lengend Snippet: GLUT1 immunostaining in cancer. Strong GLUT1 immunostaining in clear cell renal cell carcinoma ( A ), urothelial carcinoma ( B ), colorectal carcinoma ( C ), serous high-grade ovarian carcinoma ( D ), squamous cell carcinoma of the vulva ( E ), endometrioid endometrial carcinoma ( F ), enbryonel carcinoma of the testis ( G ), and absence of GLUT1 immunostaining in hepatocellular carcinoma ( H )

Article Snippet: For the purpose of antibody validation, the normal tissue TMA was also analyzed by the rabbit polyclonal GLUT1 antibody 355 A-15 (Cell Marque, Rocklin, CA, pH 6.0, 1:200) on a DAKO autostainer Link48 according to a protocol suggested by Agilent DAKO.

Techniques: Immunostaining

Journal: BMC Cancer

Article Title: Glucose-transporter 1 (GLUT1) as a prognostic biomarker: evidence from 14,966 human tumors across 134 cancer types

doi: 10.1186/s12885-025-15527-5

Figure Lengend Snippet: Ranking order of GLUT1 immunostaining in tumors. Both the percentage of positive cases (blue dots) and the percentage of strongly positive cases (orange dots) are shown

Article Snippet: For the purpose of antibody validation, the normal tissue TMA was also analyzed by the rabbit polyclonal GLUT1 antibody 355 A-15 (Cell Marque, Rocklin, CA, pH 6.0, 1:200) on a DAKO autostainer Link48 according to a protocol suggested by Agilent DAKO.

Techniques: Immunostaining

Journal: BMC Cancer

Article Title: Glucose-transporter 1 (GLUT1) as a prognostic biomarker: evidence from 14,966 human tumors across 134 cancer types

doi: 10.1186/s12885-025-15527-5

Figure Lengend Snippet: GLUT1 immunostaining and prognosis in ( A - D ) clear cell renal cell cancer and in ( E - H ) papillary renal cell cancer. A , B ), E ), and F ) show overall survival, C ), D ), G ) and H ) show recurrence free survival. For B ), D ), F and H ), tumors were grouped in GLUT1 “low”, including negative, weak and moderate staining, and GLUT1 “high” (strong) staining

Article Snippet: For the purpose of antibody validation, the normal tissue TMA was also analyzed by the rabbit polyclonal GLUT1 antibody 355 A-15 (Cell Marque, Rocklin, CA, pH 6.0, 1:200) on a DAKO autostainer Link48 according to a protocol suggested by Agilent DAKO.

Techniques: Immunostaining, Staining

Journal: Poultry Science

Article Title: Chromium picolinate alleviates heat stress-induced breast muscle glucose and lipid metabolism disorders in broiler chickens

doi: 10.1016/j.psj.2025.105704

Figure Lengend Snippet: Effects of chromium picolinate on breast muscle glycolipid metabolism genes expression of broilers under heat stress. (A) Western blot analysis. (B) GLUT1. (C) PI3K. (D) GS. (E) PPARα. (F) CPT-1. (G) LPL. Abbreviation: GLUT1: glucose transporter 1, PI3K: phosphatidylinositol 3 kinase, GS: glycogen synthase, PPARα: peroxisome proliferators-activated receptors α, CPT-1; carnitine palmitoyl transterase-1, LPL: lipoprotein lipase. In the same rank, a, b, c values with different small letter superscripts mean significant difference ( P < 0.05).

Article Snippet: Primary antibodies against GLUT1 (1:1000, AWA61570 , Abiowell), PI3K (1:1000, AWA63394 , Abiowell), GS (1:1000, AWA43660 , Abiowell), CPT1 (1:1000, AWA63836 , Abiowell), LPL (1:1000, AWA61104 , Abiowell), PPARα (1:500, BS-23398, BIOSS) and β-actin (1:2000, AWA80002 ; Abiowell) were diluted in antibody diluent (AWB0200c; Abiowell) and incubated with the membrane overnight at 4°C.

Techniques: Expressing, Western Blot